The purpose of this study is to study the relative bioavailability of AZD1981 when using a new tablet compared to the current tablet.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Enrollment
16
3x100 mg per oral, single dose in fasted state
3x100 mg per oral, single dose
3x100 mg per oral, single dose in fasted state
Research Site
Uppsala, Sweden
Assessment of the area under the plasma concentration time-curve from zero to infinity /AUC) and the maximum plasma concentration (Cmax) of AZD1981
Time frame: Pharmacokinetic (PK) sampling continuously for 60 h after each single dose, ie day 1-3 for each period.
To evaluate basic systemic PK parameters as follows:
* AUC(0-t): area under the plasma concentration versus time curve from time zero to time of last quantifiable concentration * tmax: time to reach Cmax * t1/2λz: terminal half-life * CL/F: apparent plasma clearance * MRT: apparent mean residence time * Vz/F: apparent volume of distribution during terminal phase
Time frame: PK sampling continuously for 60 h after each single dose, ie day 1-3 for each period
To evaluate the safety and tolerability of AZD1981 by assessment of adverse events, laboratory safety parameters, vital signs, ECG, physical examination and weight
Time frame: Safety will be monitored continuously and safety assessments will be made on several occasions throughout the whole study
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.